CytoTherapeutics transfers diabetes tech to Neocrin
Deal Date: Dec-01-1993 / Deal Update Date (Latest): Feb-01-1995 / Deal # 199320540
Executive Summary
In the interest of focusing exclusively on its CNS therapeutics programs, CytoTherapeutics has transferred its diabetes treatment program to Neocrin, the diabetes-focused joint venture of Baxter and TranCel, in exchange for an equity position.
